Skip to content
glp1.howSign in

Using GLP-1s

MEN 2 (multiple endocrine neoplasia type 2)

An inherited syndrome that raises the risk of medullary thyroid carcinoma and is a contraindication to most GLP-1 medications.

By the glp1.how editorial teamReviewed

MEN 2 (multiple endocrine neoplasia type 2) is an inherited syndrome that predisposes people to developing medullary thyroid carcinoma, a rare thyroid cancer.

Because of that link, GLP-1 medication labels that carry the thyroid boxed warning list two related contraindications: a personal or family history of medullary thyroid carcinoma, and having MEN 2. You can see both in the contraindications section of the Ozempic (external link) and Mounjaro (external link) prescribing information, for example.

men2multiple-endocrine-neoplasiacontraindicationsafetyglossary

Revision history

Updated 2 times since Jul 18, 2026 · show changes
  1. v3

    Body revised

  2. v2

    Summary rewritten; Body revised; Metadata updated

  3. v1

    Change tracking began

Related guides

  • Safe sharps disposal for GLP-1 injectors · Every GLP-1 injection ends with a needle you have to put somewhere. This guide walks through the FDA's two-step system: a proper sharps container (or an acceptable heavy-duty household stand-in), the short list of things never to do with a used needle, how to find your community's disposal rules, and what changes when you travel.
  • Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses · On a U-100 insulin syringe, "units" measure volume: 100 units make 1 mL. Your vial's concentration is what turns a prescribed mg dose into a unit count. This walkthrough teaches the arithmetic with worked examples at different concentrations, explains the dosing errors the FDA has documented, and gives a checklist to go through with your pharmacist. It teaches you to read the syringe. It does not prescribe doses.
  • GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk · A GLP-1 on its own rarely causes low blood sugar, but pairing it with insulin or a sulfonylurea meaningfully raises the risk. Why, how to recognize hypoglycemia, and what to settle with your prescriber before any dose changes.
  • Do GLP-1 receptors "burn out"? What long-term use actually does · A common worry is that GLP-1 receptors "burn out" with long-term use: that the drug stops working or permanently damages your natural system. Where the idea comes from, what two-year trial data show, which effect really does fade (the slowing of stomach emptying), why a plateau is a new equilibrium, and what happens to your own appetite when you stop.
  • GLP-1 myths vs. facts: what the media and social feeds get wrong · A plain-language, evidence-checked look at the most common claims about GLP-1 medications in the news and on social media: which are false, which are true, and which are still unsettled, with the studies behind each verdict.
  • Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens · Brand-name GLP-1 pens measure the dose for you. Compounded versions usually come as a vial and syringes, so you measure it yourself. Why that raises the stakes on accuracy, what to ask your pharmacy, and where compounding stands after the shortages ended.

Related terms

  • Medullary thyroid carcinoma (MTC) · A rare thyroid cancer arising from the thyroid's C cells; a personal or family history of it is a contraindication to GLP-1 medications.
  • Boxed warning · The FDA's strongest prescription-drug warning, set in a black-bordered box at the top of the label to flag a serious or life-threatening risk.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.

Was this helpful?

Improve this page